Search

Author

Subject

Date issued

Has File(s)

Search Results

Results 281-290 of 2278 (Search time: 0.005 seconds).
  • Authors: Abigael, Cohen; Thomas, Claessen; Corne van den, Berg;  Advisor: -;  Co-Author: - (2023)

    Most patients with a clinically suspected scaphoid fracture and normal initial radiograph are unnecessarily treated. Previously developed prediction rules using demographic and clinical risk are unable to accurately predict occult fractures. Adding other risk factors could enhance this. Therefore, we aim to explore if there are morphological risk factors of the wrist for sustaining a scaphoid fracture.

  • Authors: Sameh M., Hakim; Ghosoun M. A., Chikhouni; Mona A., Ammar;  Advisor: -;  Co-Author: - (2023)

    The aim of this review was to update evidence for benefit of convalescent plasma transfusion (CPT) in patients with coronavirus disease 2019 (COVID-19). Databases were searched for randomized controlled trials (RCT) comparing CPT plus standard treatment versus standard treatment only in adults with COVID-19. Primary outcome measures were mortality and need for invasive mechanical ventilation (IMV). Twenty-Six RCT involving 19,816 patients were included in meta-analysis for mortality.

  • Authors: Rongxin, Liao; Guangming, Yi; Lu, Shen;  Advisor: -;  Co-Author: - (2023)

    Emerging evidence have demonstrated that oligometastatic non-small cell lung cancer (NSCLC) can achieve clinical benefit from local consolidative therapy. Bone oligometastasis is common in advanced lung cancer, but little is known about its molecular features. The purpose of our study aimed to investigate the genomic landscape bone oligometastatic NSCLC.

  • Authors: Jang Ho, Lee; Hyung Jun, Park; Seonok, Kim;  Advisor: -;  Co-Author: - (2023)

    Idiopathic pulmonary fibrosis (IPF) is frequently accompanied by comorbidities, with the management of these comorbidities crucial for clinical outcomes. This study investigated the prevalence, incidence, changes over time, and clinical impact of comorbidities in IPF patients, based on nationwide claims data in South Korea.

  • Authors: Gizal, Nakshbandi; Catharina C., Moor; Katerina, Antoniou;  Advisor: -;  Co-Author: - (2023)

    Pulmonary fibrosis (PF) is caused by a heterogeneous group of diseases, with a high inter-individual variability in disease trajectory. Identifying disease progression in patients with PF has impact on clinical management decisions. However, strategies to early identify and predict disease progression for these patients are currently lacking. In this study, we aim to assess long-term FVC change in patients with PF measured with home spirometry, and evaluate the feasibility of a multinational patient-led registry in PF. In addition, we will assess validity of patient-reported outcomes (PROMs) for the different subgroups of patients with PF.